Relative Value

The Relative Value of one UCB stock under the Base Case scenario is 258.3 EUR. Compared to the current market price of 227.3 EUR, Ucb SA is Undervalued by 12%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

UCB Relative Value
Base Case
258.3 EUR
Undervaluation 12%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
3
vs Industry
24
Median 3Y
4.5
Median 5Y
3.1
Industry
2.7
Forward
5.9
vs History
42
vs Industry
14
Median 3Y
37
Median 5Y
28.8
Industry
22.3
Forward
28.6
vs History
20
vs Industry
16
Median 3Y
24
Median 5Y
15.1
Industry
16.8
vs History
33
vs Industry
9
Median 3Y
42.4
Median 5Y
32.5
Industry
23.1
vs History
1
vs Industry
22
Median 3Y
2.6
Median 5Y
2.2
Industry
2.3
vs History
4
vs Industry
22
Median 3Y
4.8
Median 5Y
3.4
Industry
2.9
Forward
6.1
vs History
7
vs Industry
27
Median 3Y
6.7
Median 5Y
4.7
Industry
5.6
vs History
26
vs Industry
16
Median 3Y
16
Median 5Y
13.3
Industry
13.2
Forward
20.2
vs History
46
vs Industry
10
Median 3Y
35.8
Median 5Y
22.5
Industry
16.9
Forward
28.6
vs History
22
vs Industry
15
Median 3Y
24.5
Median 5Y
17
Industry
15.6
vs History
25
vs Industry
13
Median 3Y
34.5
Median 5Y
25.4
Industry
18.4
vs History
1
vs Industry
26
Median 3Y
2.1
Median 5Y
1.8
Industry
1.9

Multiples Across Competitors

UCB Competitors Multiples
Ucb SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
BE
Ucb SA
XBRU:UCB
42.9B EUR 6.3 32.4 17.8 24
US
Eli Lilly and Co
NYSE:LLY
973.3B USD 16.4 52.7 35.5 38.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
480.6B USD 5.2 19.1 15.7 20.3
CH
Roche Holding AG
SIX:ROG
245.6B CHF 4 26 11.7 13.3
UK
AstraZeneca PLC
LSE:AZN
210.6B GBP 4.8 29.4 108 158.1
CH
Novartis AG
SIX:NOVN
194.4B CHF 4.4 17.1 10.8 13.9
US
Merck & Co Inc
NYSE:MRK
236.6B USD 3.7 12.5 8.9 10.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.7
IE
Endo International PLC
LSE:0Y5F
202B USD 87.1 -69.1 320.4 803.4
US
Pfizer Inc
NYSE:PFE
143.9B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
BE
Ucb SA
XBRU:UCB
Average P/E: 24.1
32.4
34%
1
US
Eli Lilly and Co
NYSE:LLY
52.7
50%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
26
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.4
38%
0.8
CH
Novartis AG
SIX:NOVN
17.1
18%
0.9
US
Merck & Co Inc
NYSE:MRK
12.5
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
31%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
BE
Ucb SA
XBRU:UCB
Average EV/EBITDA: 399.3
17.8
32%
0.6
US
Eli Lilly and Co
NYSE:LLY
35.5
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.7
8%
2
CH
Roche Holding AG
SIX:ROG
11.7
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
108
10%
10.8
CH
Novartis AG
SIX:NOVN
10.8
6%
1.8
US
Merck & Co Inc
NYSE:MRK
8.9
7%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
6%
1.5
IE
E
Endo International PLC
LSE:0Y5F
320.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
BE
Ucb SA
XBRU:UCB
Average EV/EBIT: 1 709.5
24
50%
0.5
US
Eli Lilly and Co
NYSE:LLY
38.1
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.3
14%
1.5
CH
Roche Holding AG
SIX:ROG
13.3
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
158.1
22%
7.2
CH
Novartis AG
SIX:NOVN
13.9
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.6
9%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
6%
1.8
IE
E
Endo International PLC
LSE:0Y5F
803.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1